The PennZone

International Collaboration Aims to Ensure More Equitable Access to Transformative Personalized Cancer Therapy

PHILADELPHIA, May 23, 2022 /PRNewswire/ -- Penn Medicine and Children's Hospital of Philadelphia (CHOP), who together pioneered the research and development of the world's first personalized cellular therapy for cancer — also known as CAR T cell therapy — have announced plans with Costa Rica's CCSS, or the Caja Costarricense de Seguro Social (Social Security Program), to facilitate CAR T research in Costa Rica. The effort is a step toward global equity in clinical research opportunities involving the use of CAR T cell therapies, which represent a leading-edge approach to cancer care not widely available across the world.

More on The PennZone

• Preston Dermatology & Skin Surgery Center Wins Gold and Bronze in Prestigious Annual DIAMOND Awards
• David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District
• Pawprint Oxygen Turns Pet Safety Viral With "Pets Live Here" Window Decals — Helping First Responders Save Lives
• "Phinge Unveil™" Coming to Las Vegas to Showcase Netverse Patented Verified App-less Platform, AI & Modular Hardware Including Developer Conferences
• Elizabeth McLaughlin, Founder and CEO of Red Wagon Group, named 2026 Presidential Leadership Scholar

---

Show All News | Report Violation